Literature DB >> 15808239

New treatments for age-related macular degeneration.

Andrew P Schachat.   

Abstract

Mesh：

Substances：

Year:  2005        PMID： 15808239     DOI： 10.1016/j.ophtha.2005.01.018

Source DB:  PubMed          Journal:  Ophthalmology        ISSN： 0161-6420            Impact factor:   12.079


× No keyword cloud information.
  7 in total

1.  Which treatment is best for which AMD patient?

Authors:  P Kroll; C H Meyer
Journal:  Br J Ophthalmol       Date:  2006-02       Impact factor: 4.638

Review 2.  Aptamers as a novel tool for diagnostics and therapy.

Authors:  Onat Kadioglu; Anna Helena Malczyk; Henry Johannes Greten; Thomas Efferth
Journal:  Invest New Drugs       Date:  2015-02-01       Impact factor: 3.850

3.  Single-stranded DNA aptamer targeting and neutralization of anti-D alloantibody: a potential therapeutic strategy for haemolytic diseases caused by Rhesus alloantibody.

Authors:  Yinze Zhang; Fan Wu; Manni Wang; Naibao Zhuang; Huayou Zhou; Hua Xu
Journal:  Blood Transfus       Date:  2016-11-11       Impact factor: 3.443

4.  Triamcinolone acetonide suppresses early proangiogenic response in retinal pigment epithelial cells after photodynamic therapy in vitro.

Authors:  R Obata; A Iriyama; Y Inoue; H Takahashi; Y Tamaki; Y Yanagi
Journal:  Br J Ophthalmol       Date:  2006-09-20       Impact factor: 4.638

5.  A therapeutic aptamer inhibits angiogenesis by specifically targeting the heparin binding domain of VEGF165.

Authors:  Joon-Hwa Lee; Marella D Canny; Andrea De Erkenez; Dominik Krilleke; Yin-Shan Ng; David T Shima; Arthur Pardi; Fiona Jucker
Journal:  Proc Natl Acad Sci U S A       Date:  2005-12-15       Impact factor: 11.205

Review 6.  Targeting vascular endothelial growth factor: a promising strategy for treating age-related macular degeneration.

Authors:  Michael Waisbourd; Anat Loewenstein; Michaella Goldstein; Igal Leibovitch
Journal:  Drugs Aging       Date:  2007       Impact factor: 3.923

7.  Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an in silico study.

Authors:  Arpita Devi; Nyshadham S N Chaitanya
Journal:  Mol Divers       Date:  2021-01-02       Impact factor: 3.364
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.